Study: Selenium may fight prostate cancer
BUFFALO, N.Y., April 17 (UPI) -- A U.S. study suggests selenium might
offer an intervention strategy for the treatment of prostate cancer.
Yan Hu of the Roswell Park Cancer Institute said selenium, an effective
chemopreventive agent for prostate cancer, has been found to
down-regulate interleukin-6, of IL-6 -- a cytokine that induces the
progression of the spread of androgen-independent prostate cancer cells.
Most prostate cancer patients respond initially to anti-androgen
therapy, but virtually all patients relapse due to the growth of
androgen-independent tumor cells promoted by the overexpression of IL-6.
Hu posits down-regulation of the cytokine by selenium might present an
interventional strategy in prostate cancer therapy.
He presented his study Monday in Los Angeles during the 2007 centennial
meeting of the American Association for Cancer Research.
The Roswell Park Cancer Institute, founded in 1898 in Buffalo, N.Y., is
the nation's first cancer research, treatment and education center.
Copyright 2007 by United Press International. All Rights Reserved.
http://tinyurl.com/ysrtwn